IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 06-346)

Application of:	**Martin Andrew Crockard et al.**	)	
		)	
Serial No.:	**To Be Assigned**	)	**Group Art Unit: TBA**
		)	
Int'l Serial No.:	**PCT/GB04/004713**	)	**Examiner: TBA**
		)	
Filing Date:	**Herewith**	)	
		)	**Confirmation No.: TBA**
Title: Molecular Marker		)	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Dear Sir:

Please consider the following amendments and remarks.

Amendments to the claims begin on page 2.

Remarks **begin on page** 4.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A method for the detection of the presence of or the risk of cancer in a patient comprising the step of detecting in an isolated sample the presence or expression of the gene characterised by the nucleotide sequence identified as SEQ ID NO. 1, wherein the presence or expression of the gene indicates the presence of or the risk of cancer in the patient from whom the sample was isolated.

2. (Original) A method according to claim 1, wherein the gene is that identified as SEQ ID NO. 2.

3. (Currently Amended) A method according to claim 1 ~~or claim 2~~, wherein the sample is obtained from breast tissue, the uterus, testis or ovary.

4. (Currently Amended) A method according to ~~any proceeding~~ claim 1, wherein the cancer is breast cancer.

5. (Currently Amended) A method according to ~~any proceeding~~ claim 1, wherein detection is carried out by amplifying the gene using the polymerase enzyme.

6. (Original) An isolated polynucleotide comprising the nucleotide sequence identified herein as SEQ ID No. 1, or its complement, or a polynucleotide of at least 15 consecutive nucleotides that hybridises to the sequence (or its complement) under stringent hybridising conditions.

7. (Original) An isolated polynucleotide according to claim 6, wherein the sequence is that identified herein as SEQ ID No. 1.

8. (Canceled)

9. (Canceled)

10. (Original) A peptide comprising the sequence identified herein as SEQ ID no. 3, or a fragment thereof of at least 10 consecutive amino acid residues.

11. (Original) An antibody having an infinity of at least 10^{-6} M for the peptide of claim 10.

12. (Canceled)

13. (Canceled)

REMARKS

The claims of this U.S. national phase of a PCT application were amended to reduce the number of claims and remove multiple dependencies in order to reduce the filing fee. No new subject matter has been added, nor has the scope of the claims been amended.

Enclosed herewith is the ISR and Form SB/08a listing the art cited in the ISR. We understand copies of the art cited in the ISR will be forwarded to the PTO by the International Authorities.

If there are any questions or comments regarding this Preliminary Amendment or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Respectfully submitted,

Date: May 9, 2006

/Michael S. Greenfield/
Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff LLP
300 South Wacker Drive
Chicago, IL 60606
Telephone: 312-913-0001
Facsimile: 312-913-0002